Article Text
Statistics from Altmetric.com
- antilipaemic agents (cardiovascular diseases)
- cholesterol
- diabetes mellitus (type 2)
- dyslipidaemias
- procetofen
- triglycerides
Q In patients with type 2 diabetes mellitus, what is the effect of long term fenofibrate therapy on coronary heart disease (CHD) events?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Geriatrics ★★★★★☆☆
METHODS
Design
randomised placebo-controlled trial (Fenofibrate Intervention and Event Lowering in Diabetes [FIELD]).
Allocation
concealed.*
Blinding
blinded (clinicians, patients, and outcome assessors).*
Follow up period
median 5 years.
Setting
63 centres in Australia, New Zealand, and Finland.
Patients
9795 patients 50–75 years of age (mean age 62 y, 63% men) who had a World Health Organization diagnosis of type 2 diabetes, total cholesterol concentration 3–6.5 mmol/l, and a total cholesterol/high density lipoprotein (HDL) cholesterol ratio ⩾4 or a triglyceride concentration of 1–5 mmol/l, with no clear indication for lipid modifying therapy. Exclusion criteria were renal impairment, chronic liver disease, symptomatic gallbladder disease, or occurrence of a cardiovascular disease (CVD) event within 3 months …
Linked Articles
- Glossary